Gossamer Bio Faces Securities Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy GOSS?
Source: PRnewswire
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, indicating potential missteps in clinical trial design affecting investors who purchased shares between June 16, 2025, and February 20, 2026.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting a severe loss of investor confidence in the company's future prospects, which may jeopardize its listing status on Nasdaq.
- Legal Investigation: Hagens Berman has initiated an investigation into Gossamer's disclosures regarding the PROSERA trial design, particularly focusing on the transparency of patient recruitment and monitoring protocols, which could significantly impact investor decisions and trust.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to submit claims, highlighting the erosion of confidence in the management's assurances regarding trial outcomes, which may complicate future fundraising efforts and market credibility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.446
Low
10.00
Averages
12.33
High
15.00
Current: 0.446
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, alleging the company misled investors regarding the viability of its PROSERA study.
- Study Results Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Investor Losses: The concealment of critical adverse facts regarding the study design led shareholders to purchase securities at artificially inflated prices, resulting in significant losses as the stock price dropped from $2.13 to $0.42.
- Shareholder Action Advice: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by June 1, 2026, and those who choose not to participate can remain absent class members eligible for recovery.
See More
Multiple Companies Face Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is accused of failing to disclose risks of declining advertising revenues during the period from February 2025 to February 2026, potentially leading to imminent restructuring and significant negative impacts on future financial performance.
- New Era Energy Allegations: New Era Energy & Digital, Inc. is charged with overstating progress on its Texas data center project and engaging in fraudulent schemes to transfer oil and gas wells to evade costs, which could result in misleading financial results and erode investor confidence.
- Gossamer Bio Study Failure: Gossamer Bio, Inc. failed to meet the primary endpoint in its clinical trial from 2025 to 2026, as patients performed well on placebo, leading to accusations that the company's prior positive statements were misleading, potentially affecting its stock price.
- Medpace Holdings Misrepresentation: Medpace Holdings, Inc. is accused of exaggerating its projected book-to-bill ratio for Q4 2025 and failing to adequately assess the impact of cancellations, which could undermine investor confidence in the company's future performance.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, indicating potential missteps in clinical trial design affecting investors who purchased shares between June 16, 2025, and February 20, 2026.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting a severe loss of investor confidence in the company's future prospects, which may jeopardize its listing status on Nasdaq.
- Legal Investigation: Hagens Berman has initiated an investigation into Gossamer's disclosures regarding the PROSERA trial design, particularly focusing on the transparency of patient recruitment and monitoring protocols, which could significantly impact investor decisions and trust.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to submit claims, highlighting the erosion of confidence in the management's assurances regarding trial outcomes, which may complicate future fundraising efforts and market credibility.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) is facing allegations for failing to disclose critical facts regarding its clinical trial failures during the class period from June 16, 2025, to February 20, 2026, misleading investors, with a lead plaintiff motion deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is accused of overstating progress on its Texas data center project and engaging in fraudulent activities from November 6, 2024, to December 29, 2025, with investors needing to act by June 1, 2026, to protect their rights.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is under scrutiny for making false statements about its financial health during the period from April 22, 2025, to February 9, 2026, with a lead plaintiff motion deadline of June 5, 2026, potentially exposing investors to financial losses.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors holding shares in the aforementioned companies and suffering losses to contact their firm promptly to understand their legal rights and ensure proper representation in the class actions.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Gossamer Bio and certain officers, alleging violations of federal securities laws from June 16, 2025, to February 20, 2026, seeking to recover damages for affected investors.
- False Statements Allegation: The complaint claims that defendants misled investors by touting positive results from the PROSERA study while concealing significant adverse facts regarding the study's design at Latin American sites, resulting in artificially inflated stock prices that harmed investors.
- Investor Participation Call: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, allowing them to share in any recovery without needing to serve as lead plaintiffs, thus broadening participation in the lawsuit.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors in securities fraud class actions, emphasizing their commitment to restoring investor capital and ensuring corporate accountability in the marketplace.
See More
Faruqi & Faruqi Investigates Gossamer Bio Investor Losses
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Gossamer Bio, Inc. for investors who purchased securities between June 16, 2025, and February 20, 2026, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that June 1, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of investor participation in legal proceedings.
- Direct Contact Channels: Investors who suffered losses are encouraged to contact Faruq & Faruq partner Josh Wilson directly, with multiple contact options provided to facilitate consultations, demonstrating the firm's commitment to client service.
- Market Impact: This investigation could negatively affect Gossamer's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, alleging the company misled investors regarding the viability of its PROSERA study.
- Study Results Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Investor Losses: The concealment of critical adverse facts regarding the study design led shareholders to purchase securities at artificially inflated prices, resulting in significant losses as the stock price dropped from $2.13 to $0.42.
- Shareholder Action Advice: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by June 1, 2026, and those who choose not to participate can remain absent class members eligible for recovery.
See More
Multiple Companies Face Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is accused of failing to disclose risks of declining advertising revenues during the period from February 2025 to February 2026, potentially leading to imminent restructuring and significant negative impacts on future financial performance.
- New Era Energy Allegations: New Era Energy & Digital, Inc. is charged with overstating progress on its Texas data center project and engaging in fraudulent schemes to transfer oil and gas wells to evade costs, which could result in misleading financial results and erode investor confidence.
- Gossamer Bio Study Failure: Gossamer Bio, Inc. failed to meet the primary endpoint in its clinical trial from 2025 to 2026, as patients performed well on placebo, leading to accusations that the company's prior positive statements were misleading, potentially affecting its stock price.
- Medpace Holdings Misrepresentation: Medpace Holdings, Inc. is accused of exaggerating its projected book-to-bill ratio for Q4 2025 and failing to adequately assess the impact of cancellations, which could undermine investor confidence in the company's future performance.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, indicating potential missteps in clinical trial design affecting investors who purchased shares between June 16, 2025, and February 20, 2026.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting a severe loss of investor confidence in the company's future prospects, which may jeopardize its listing status on Nasdaq.
- Legal Investigation: Hagens Berman has initiated an investigation into Gossamer's disclosures regarding the PROSERA trial design, particularly focusing on the transparency of patient recruitment and monitoring protocols, which could significantly impact investor decisions and trust.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to submit claims, highlighting the erosion of confidence in the management's assurances regarding trial outcomes, which may complicate future fundraising efforts and market credibility.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) is facing allegations for failing to disclose critical facts regarding its clinical trial failures during the class period from June 16, 2025, to February 20, 2026, misleading investors, with a lead plaintiff motion deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is accused of overstating progress on its Texas data center project and engaging in fraudulent activities from November 6, 2024, to December 29, 2025, with investors needing to act by June 1, 2026, to protect their rights.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is under scrutiny for making false statements about its financial health during the period from April 22, 2025, to February 9, 2026, with a lead plaintiff motion deadline of June 5, 2026, potentially exposing investors to financial losses.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors holding shares in the aforementioned companies and suffering losses to contact their firm promptly to understand their legal rights and ensure proper representation in the class actions.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Gossamer Bio and certain officers, alleging violations of federal securities laws from June 16, 2025, to February 20, 2026, seeking to recover damages for affected investors.
- False Statements Allegation: The complaint claims that defendants misled investors by touting positive results from the PROSERA study while concealing significant adverse facts regarding the study's design at Latin American sites, resulting in artificially inflated stock prices that harmed investors.
- Investor Participation Call: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, allowing them to share in any recovery without needing to serve as lead plaintiffs, thus broadening participation in the lawsuit.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors in securities fraud class actions, emphasizing their commitment to restoring investor capital and ensuring corporate accountability in the marketplace.
See More
Faruqi & Faruqi Investigates Gossamer Bio Investor Losses
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Gossamer Bio, Inc. for investors who purchased securities between June 16, 2025, and February 20, 2026, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that June 1, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of investor participation in legal proceedings.
- Direct Contact Channels: Investors who suffered losses are encouraged to contact Faruq & Faruq partner Josh Wilson directly, with multiple contact options provided to facilitate consultations, demonstrating the firm's commitment to client service.
- Market Impact: This investigation could negatively affect Gossamer's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
